{
    "nct_id": "NCT04246177",
    "official_title": "A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)",
    "inclusion_criteria": "* Has a diagnosis of HCC confirmed by radiology, histology, or cytology\n* Has HCC localized to the liver and not amenable to curative treatment\n* Participants with Hepatitis C virus (HCV) are eligible if treatment was completed at least 1 month prior to starting study intervention\n* Participants with Hepatitis B virus (HBV) are eligible\n* Has adequately controlled blood pressure with or without antihypertensive medications\n* Has adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Is currently a candidate for liver transplantation\n* Has had gastric bleeding within the last 6 months\n* Has ascites that is not controlled with medication\n* Has significant cardiovascular impairment within 12 months of the first dose of study intervention such as congestive heart failure\n* Has a serious nonhealing wound, ulcer, or bone fracture\n* Has received locoregional therapy to existing liver lesions",
    "miscellaneous_criteria": ""
}